04.02.25 -- How Is The Market Responding To Brisk HPAPI Demand?

This webinar explores 3D screen printing in pharmaceutical manufacturing, a breakthrough overcoming scalability and formulation challenges of traditional 3D printing. It enables precise layering for multi-functional tablets with customizable drug release profiles, enhancing efficacy and patient convenience. Attendees will learn how this cost-effective, scalable technology optimizes pharmacokinetics, reduces API use, and offers new IP opportunities. Click here to learn more.

Chief Editor Louis Garguilo provides a succinct update on the Act, and broadens the discussion to other challenges on the horizon.

Robert Discordia, Co-Founder, President and CEO, EQUULUS Therapeutics, knows that to advance early-stage development assets most economically, biotechs should (a) stay within their virtual model, and (b) base that outsourcing strategy on initial business objectives. Here are his dos and don'ts.

Predicting blending quality doesn't have to be a guessing game. Learn how to leverage virtual prototypes to make informed decisions and minimize costly trial-and-error in tablet manufacturing.

Explore a comprehensive overview of the challenges, requirements, and best practices for safely working with highly potent compounds in drug development and manufacturing.

The pharmaceutical industry is undergoing a transformative shift from batch to continuous flow processes, enabling enhanced efficiency and safety as well as improved sustainability.

Gain critical insights into nitrosamine control strategies, regulatory requirements, and advanced analytical methods to ensure compliance by August 2025.

Regulatory agencies prefer terminal sterilization over aseptic manufacturing, but is it suitable for your product? Industry manufacturing experts guide you in the selection and final delivery.

A comprehensive approach to evaluating drug molecules for the selection of a lead solid form and formulation can significantly accelerate development timelines and limit risks in later development.

Early identification of potential absorption risks is critical for rapid and efficient drug development. Lonza's PBPK modeling services are designed to de-risk your drug development program.

It's not just about the science, but also about partnering with clients to create future opportunities and ensuring their needs are met, even when timelines are tight.

Leverage Pharma Expanse’s global network of nine manufacturing sites across five countries to streamline your outsourcing solutions, from discovery to commercial production.